News & Events
September 4, 2018
Pall Corporation and Celltheon form strategic partnership for biotherapeutics development and manufacturing with Celltheon SMART Expression Platform
PORT WASHINGTON, NY - September 4, 2018: Pall Corporation, a global leader in filtration, separation and purification, has formed a strategic partnership with Celltheon Corporation, an experienced cell line and expression technology platform development company. This partnership aligns Pall Biotech equipment and consumables with the Celltheon SMART™ Expression Platform to deliver integrated manufacturing solutions for customers developing biotherapeutics. It is part of Pall’s strategic approach to forming key partnerships that help enable better, safer and faster biologic production.
“The Pall Biotech portfolio was built to support drug manufacturers at all stages of biotherapeutic molecule development and processes to improve biologic production, and ultimately, global health,” said Mario Philips, VP and General Manager of Pall Biotech. “Pall’s strategic partnerships, such as this one with Celltheon, aim to overcome manufacturing challenges with efficient, integrated and cost-effective total solutions.”
“The Celltheon SMART™ Expression Platform is an off-the-shelf, fully validated mammalian cell platform used to develop biologics and it is well complemented by the Pall Biotech line of equipment and services,” said Amita Goel, CEO, founder and chairman of Celltheon. “With the complementary Celltheon and Pall technologies, we can provide an integrated end-to-end solution for research and bioproduction that is cost effective and time efficient. This partnership with Pall Corporation is in line with Celltheon’s mission to expedite drug development and provide solutions for unmet needs in bioprocessing.”
Through the agreement, Celltheon customers will have immediate access to various Pall Biotech upstream and downstream processing technologies, including bioreactors, mixing and storage, downstream technologies, and consumables.
About Pall Corporation
Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide.
For more information visit www.pall.com
About Celltheon Corporation
Celltheon Corporation is focused on cell line and process development for biologics manufacturing. The team offers off-the-shelf, yet customizable solutions for the expression of a wide variety of recombinant proteins via the proprietary Celltheon SMART™ Expression Platform of technologies and services. Celltheon has developed and integrated consistent and high productivity technologies at every step in the upstream bioproduction process. The Celltheon SMART™ Expression Platform has been validated on a number of pre-clinical and clinical stage molecules. Learn more about reducing time and cost to market with the right partner at http://www.celltheon.com
For more information on working with Celltheon, please contact firstname.lastname@example.org
Pall Corporate Media Contact
Director of Communications
Pall Media Contact
White Matter Communications
April 10, 2017
Don't Buy New Cell Line or RCB !! Save Millions by Doing This Instead...
March 14-17, 2016
BioProcess International, West Coat in Oakland California
Celltheon to give Keynote address
January 5th, 2016
Celltheon expands and moves to new location in Union City
CEO Teaches Mammalian Cell Culture Intensive at KGI
May 18-20th, 2015
Cell line development and Engineering conference
Celltheon presents data on Celltheon's SMART Expression Platform a novel technology for generating manufacturing cell lines.
January 21, 2015
CHI PepTalk Presentation & Buzz Session
Celltheon to present at CHI PEP in San Diego. The talk is on Celltheon's SMART expression system. Meet up with Celltheon employees at the CHO sub session during the podium presentation and the followup buzz sessions.
October 21-25, 2014
Amita Goel to teach Mammalian Cell Culture Intensive at KGI
Advances in mammalian cell technology over the past three decades, combined with major developments in therapeutic proteins and antibodies, have made the recombinant Chinese Hamster Ovary (CHO) cells the expression of choice in biotech manufacturing. In traditional mechanically stirred bioreactors, production levels have increased 10,000-fold during the same period and product protein titers are now routinely measured in grams per liter. These achievements are leading to significant cell culture bioprocess sophistication, and, along with emerging single use technologies, are making the future flexible bioprocess manufacturing a distinct possibility. This five day intensive laboratory based course is designed for professional scientists and engineers who wish to enhance their basic knowledge and training in upstream functional areas including cell culture and primary recovery. The primary goal of the course is to update the participants' background in mammalian cell biotechnology, from cell line design, development and optimization to bioreactor design, scale up and operation. The course will be delivered by a team of senior industry and academic experts at the Amgen Bioprocessing Center (ABC) at Keck Graduate Institute in Claremont, California, from July 21-25, 2014.
June 23-26, 2014
BIO International Convention in San Diego
We look forward to seeing you in San Diego.
June 10-11, 2014 ManuBio
CELLTHEON Presents at The Annual Bio Manufacturing & Process Innovation Leaders Summit in Boston
CEO presents on development of innovative and cost effective solutions in bioprocessing.
April 15, 2014
CELLTHEON Presents at Bio2Device
Biotherapeutic drug development continues to be a rapidly growing field and a large number of these drugs, like monoclonal antibodies have been approved for treatment of patients. It is estimated that hundreds of new monoclonal antibodies could enter preclinical and clinical development each year. There is still considerable unmet medical need in the three main areas of study - cancer, immunological and infectious diseases, and these emerging agents could provide valuable new treatment options. Also with the growth in Biosimilar, the global competition for biologics manufacturing has put immense pressure to shorten time to market. Growth and state of the art in the biotechnology industry promises to shrink developmental workflows by substituting time-intensive steps with rapid ones, thus shortening product and process development timelines.
March 5, 2014
CELLTHEON Hosted by EPPIC
Biotherapeutic drug development continues to be a rapidly growing field. A large number of these drugs, like monoclonal antibodies, have been approved for treatment of patients with cancer, inflammatory disease and multiple rare diseases due to their highly targeted and specific nature. Researchers are in constant need of novel and unique technologies that allow them to develop biotherapeutics faster in order to accelerate their drugs into the clinic. However regulatory demands continue to be high and robust and reproducible processes are required to meet them. Join us for a panel discussion on current technologies related to various mammalian expression systems, process optimization methods, downstream purification technologies, large scale manufacturing and various analytical tools to support the development of these drugs.
Janurary 23, 2014
CELLTHEON CEO Presents at ISPE CEO Night
The ISPE San Francisco chapter hosts their yearly CEO Night featuring three industry leaders, including Amita Goel from CELLTHEON, Stefan Ryser form Trellis Bioscience LLC and Marie- Cecile van de Lavoir from Crystal Bioscience.